Study title: A phase I evaluation of oral and intravenous vinorelbine tartrate in Paediatric Cancer Patients
Type of medicine: Medicines containing chemical active substances | |||||
Therapeutic area: Neoplasms | |||||
Brands: Please see report, Please see report, Please see report, Please see report, Please see report, Please see report | |||||
MAH holders: Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please s... | |||||
Assessment: | |||||
Active substance: VINORELBINE | |||||
ATC code: L01CA05 | |||||
Document link: | |||||
Document date: 2011-08-08 | |||||
Study number: CCG0936 | |||||
EudraCT number: | |||||
Scope of study: Clinical | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | Y | Y | Y |